Other Posts
What makes an “observation” an “insight” in the world of Medical Affairs? This is the question tackled by MedicalAffairs professionals on this month’s Elevate podcast from the Medical Affairs Professionals Society (MAPS).
What makes an “observation” an “insight” in the world of Medical Affairs? This is the question tackled by Medical Affairs professionals on this month’s Elevate podcast from the Medical Affairs Professionals Society (MAPS).
LARVOL VP of Marketing Abby Fraser joined industry experts Carol Collins-Carriveau, Senior Director of Medical Sciences at Gilead Sciences, and Jennifer Schneider, Director of Field Medical Alignment at Novo Nordisk, to unpack this important topic.
Collectively, the group talked about how to tell the difference between insights and observations in Medical Affairs, and how those insights are collected and used in the industry. The insights collected by Medical Affairs teams factor not only into medical strategy but also strategy across entire companies, shaping clinical development as well as commercial strategy.
Click below to listen to the full 20-minute conversation which covers:
LARVOL is pleased to sponsor this conversation through MAPS and to work with the Medical Affairs teams at Gilead and Novo Nordisk to achieve their strategic goals. Learn more about our digital tools to support insight generation by requesting a demo of OMNI, our KOL monitoring digest and online platform.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
